23andMe Inc. (ME): רווח למניה בשנים עשר החודשים האחרונים

23andMe Holding Co. (ME) maintains a resilient business model due to US data localization, which eliminates external pressure. The rolling net income per share on the GURU.Markets chart has stabilized at -15.81. Unique patents and strict FDA oversight ensure the company's dominance. 23andMe Holding Co. (ME) generates revenue through the sale of genetic tests and by providing the largest pharmaceutical behemoths with access to its biobank.
פילוחי מדדים פיננסיים ומדדי שוק עבור 23andMe Inc (ME)

Separating stable assets from speculative instruments requires an analysis of the actual yield per security. For 23andMe Holding Co. (ME), this process is complicated by the intensive liquidity burn associated with biotechnological research. The annual net income per share trend measures the final financial result for the year divided by the number of shares. This metric reveals the business's actual ability to generate value. Current price action confirms a critical depletion of the company's reserves.